Johns Hopkins Medicine: Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Patients With Advanced Lung Cancer
December 13, 2023
December 13, 2023
BALTIMORE, Maryland, Dec. 13 (TNSres) -- Johns Hopkins Medicine issued the following news release:
Using a "liquid biopsy" to study genetic material from tumors shed into the bloodstream together with immune cells could help clinicians predict which patients with advanced lung cancers are responding to immunotherapies and which patients may develop immune-related side effects several months later, according to research directed by investigators at the Johns Hopkins Kimmel . . .
Using a "liquid biopsy" to study genetic material from tumors shed into the bloodstream together with immune cells could help clinicians predict which patients with advanced lung cancers are responding to immunotherapies and which patients may develop immune-related side effects several months later, according to research directed by investigators at the Johns Hopkins Kimmel . . .